Monday, October 26, 2026

Monetary Policy & Markets

2 articles

ECB Signals Further Cuts While Fed Independence Concerns Add Political Risk Premium to Dollar Assets

ECB Signals Further Cuts While Fed Independence Concerns Add Political Risk Premium to Dollar Assets

European Central Bank officials signaled room for additional rate cuts amid favorable inflation data, while emerging market central banks in Indonesia, Chile, and Uruguay maintain data-dependent easing stances. Political uncertainty surrounding Fed Chair Jerome Powell's May 2026 term expiration is creating measurable risk premiums as markets price in potential Trump administration pressure for looser monetary policy.

ViaNews Editorial Team (Markets)•
Social Security Insolvency Now Projected for 2032 as Fed Chair Succession Looms in May 2026

Social Security Insolvency Now Projected for 2032 as Fed Chair Succession Looms in May 2026

The One Big Beautiful Bill Act accelerates Social Security's insolvency from 2035 to 2032 through tax cuts reducing federal revenue, while slashing $1.1 trillion from Medicaid. Jerome Powell's Fed Chair term expires May 2026, creating succession uncertainty as the next chair faces pressure to balance presidential loyalty against market credibility during an entitlement crisis.

ViaNews Editorial Team (Markets)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com